NCT01836341View on ClinicalTrials.gov

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Afatinib

DRUG

Cisplatin

DRUG

Carboplatin

DRUG

Pemetrexed

RADIATION

Radiation therapy

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01836341 - Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation | Biotech Hunter | Biotech Hunter